Damage and Progression on Radiographs in Individual Joints: Data from Pivotal Randomized Controlled Trials

REFERENCES

1. 1.↵
   1. Strand V,
   2. Sharp JT

   . Radiographic data from recent randomized controlled trials in rheumatoid arthritis: What have we learned? Arthritis Rheum 2003;48:21–34.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Welsing PM,
   2. Landewe RB,
   3. van Riel PL,
   4. Boers M,
   5. van Gestel AM,
   6. van der Linden S,
   7. et al.

   The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis. Arthritis Rheum 2004;50:2082–93.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Welsing PM,
   2. van Gestel AM,
   3. Swinkels HL,
   4. Kiemeney LA,
   5. van Riel PL,
   6. Laan RF,
   7. et al.

   The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum 2001;44:2009–17.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Drossaers-Bakker K,
   2. Kroon H,
   3. Zwinderman A,
   4. Breedveld F,
   5. Hazes J

   . Radiographic damage of large joints in long-term rheumatoid arthritis and its relation to function. Rheumatology 2000;39:998–1003.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Dumonde DC,
   2. Jasani JK

   1. Larsen A,
   2. Dale K

   . Standardized radiological evaluation of rheumatoid arthritis in therapeutic trials. In: Dumonde DC, Jasani JK, editors. Recognition of anti-rheumatic drugs. Lancaster: MTP Press; 1977:285–92.
6. 6.↵
   1. Scott D,
   2. Houssien D,
   3. Laasonen L

   . Proposed modification to Larsen’s scoring method for hand and wrist radiographs. Br J Rheumatol 1995;34:56.

   OpenUrlFREE Full Text
7. 7.↵
   1. Rau R,
   2. Herborn G

   . A modified version of Larsen’s scoring method to assess radiologic changes in rheumatoid arthritis. J Rheumatol 1995;22:1976–82.

   OpenUrlPubMed
8. 8.↵
   1. Sharp JT,
   2. Young DY,
   3. Bluhm GB,
   4. Brook A,
   5. Brower AC,
   6. Corbett M,
   7. et al.

   How many joints in the hands and wrists should be included in a score of radiologic abnormalities used to assess rheumatoid arthritis? Arthritis Rheum 1985;28:1326–35.

   OpenUrlPubMed
9. 9.↵
   1. van der Heijde DM

   . Plain X-rays in rheumatoid arthritis: overview of scoring methods, their reliability and applicability. Baillieres Clin Rheumatol 1996;10:435–53.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Genant HK

    . Methods of assessing radiographic change in rheumatoid arthritis. Am J Med 1983;75:35–47.

    OpenUrlPubMed
11. 11.↵
    1. Bruynesteyn K,
    2. van der Heijde D,
    3. Boers M,
    4. van der Linden S,
    5. Lassere M,
    6. van der Vleuten C

    . The Sharp/van der Heijde method out-performed the Larsen/Scott method on the individual patient level in assessing radiographs in early rheumatoid arthritis. J Clin Epidemiol 2004;57:502–12.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Emery P,
    2. Breedveld FC,
    3. Hall S,
    4. Durez P,
    5. Chang DJ,
    6. Robertson D,
    7. et al.

    Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008;372:375–82.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Klareskog L,
    2. van der Heijde D,
    3. de Jager JP,
    4. Gough A,
    5. Kalden J,
    6. Malaise M,
    7. et al.

    Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675–81.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Keystone E,
    2. van der Heijde D,
    3. Mason D Jr.,
    4. Landewe R,
    5. Vollenhoven RV,
    6. Combe B,
    7. et al.

    Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 2008;58:3319–29.

    OpenUrlCrossRefPubMed
15. 15.↵
    1. Smolen J,
    2. Landewé RB,
    3. Mease P,
    4. Brzezicki J,
    5. Mason D,
    6. Luijtens K,
    7. et al.

    Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 2009;68:797–804.

    OpenUrlAbstract/FREE Full Text
16. 16.↵
    1. Landewé RB,
    2. van der Heijde D,
    3. Klareskog L,
    4. van Vollenhoven R,
    5. Fatenejad S

    . Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: results from the trial of etanercept and methotrexate with radiographic and patient outcomes. Arthritis Rheum 2006;54:3119–25.

    OpenUrlCrossRefPubMed
17. 17.↵
    1. Hulsmans HM,
    2. Jacobs JW,
    3. van der Heijde DM,
    4. van Albada-Kuipers GA,
    5. Schenk Y,
    6. Bijlsma JW

    . The course of radiologic damage during the first six years of rheumatoid arthritis. Arthritis Rheum 2000;43:1927–40.

    OpenUrlCrossRefPubMed
18. 18.↵
    1. van der Heijde DM,
    2. van Leeuwen MA,
    3. van Riel PL,
    4. Koster AM,
    5. van ’t Hof MA,
    6. van Rijswijk MH,
    7. et al.

    Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis. Arthritis Rheum 1992;35:26–34.

    OpenUrlPubMed